- Home
- LYRA vs BOLT Comparison
LYRA vs BOLT Comparison
Compare LYRA & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYRA
- BOLT
- Stock Information
- Founded
- LYRA 2005
- BOLT 2015
- Country
- LYRA United States
- BOLT United States
- Employees
- LYRA N/A
- BOLT N/A
- Industry
- LYRA Medical/Dental Instruments
- BOLT Biotechnology: Pharmaceutical Preparations
- Sector
- LYRA Health Care
- BOLT Health Care
- Exchange
- LYRA Nasdaq
- BOLT Nasdaq
- Market Cap
- LYRA 11.3M
- BOLT 9.4M
- IPO Year
- LYRA 2020
- BOLT 2021
- Fundamental
- Price
- LYRA $6.41
- BOLT $5.37
- Analyst Decision
- LYRA Hold
- BOLT Buy
- Analyst Count
- LYRA 1
- BOLT 3
- Target Price
- LYRA $16.00
- BOLT $47.50
- AVG Volume (30 Days)
- LYRA 14.8K
- BOLT 8.9K
- Earning Date
- LYRA 11-11-2025
- BOLT 11-11-2025
- Dividend Yield
- LYRA N/A
- BOLT N/A
- EPS Growth
- LYRA N/A
- BOLT N/A
- EPS
- LYRA N/A
- BOLT N/A
- Revenue
- LYRA $770,000.00
- BOLT $4,167,000.00
- Revenue This Year
- LYRA N/A
- BOLT N/A
- Revenue Next Year
- LYRA $123.46
- BOLT N/A
- P/E Ratio
- LYRA N/A
- BOLT N/A
- Revenue Growth
- LYRA N/A
- BOLT N/A
- 52 Week Low
- LYRA $3.81
- BOLT $4.59
- 52 Week High
- LYRA $37.50
- BOLT $14.36
- Technical
- Relative Strength Index (RSI)
- LYRA 38.58
- BOLT 52.49
- Support Level
- LYRA $6.15
- BOLT $5.04
- Resistance Level
- LYRA $6.72
- BOLT $5.50
- Average True Range (ATR)
- LYRA 0.38
- BOLT 0.23
- MACD
- LYRA -0.01
- BOLT 0.05
- Stochastic Oscillator
- LYRA 25.85
- BOLT 81.27
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.